172 related articles for article (PubMed ID: 35120732)
21. Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma.
Bartlett EK; Lee AY; Spanheimer PM; Bello DM; Brady MS; Ariyan CE; Coit DG
Br J Surg; 2020 Oct; 107(11):1480-1488. PubMed ID: 32484242
[TBL] [Abstract][Full Text] [Related]
22. Management of the positive sentinel lymph node in the post-MSLT-II era.
Bredbeck BC; Mubarak E; Zubieta DG; Tesorero R; Holmes AR; Dossett LA; VanKoevering KK; Durham AB; Hughes TM
J Surg Oncol; 2020 Dec; 122(8):1778-1784. PubMed ID: 32893366
[TBL] [Abstract][Full Text] [Related]
23. Challenges in sentinel node pathology in the era of adjuvant treatment.
Franke V; Madu MF; Bierman C; Klop WMC; van Houdt WJ; Wouters MWJM; van de Wiel BA; van Akkooi ACJ
J Surg Oncol; 2020 Oct; 122(5):964-972. PubMed ID: 32602119
[TBL] [Abstract][Full Text] [Related]
24. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era.
Mitra D; Ologun G; Keung EZ; Goepfert RP; Amaria RN; Ross MI; Gershenwald JE; Lucci A; Fisher SB; Davies MA; Lee JE; Bishop AJ; Farooqi AS; Wargo J; Guadagnolo BA
Ann Surg Oncol; 2021 Jul; 28(7):3480-3489. PubMed ID: 33856603
[TBL] [Abstract][Full Text] [Related]
25. National practice patterns of completion lymph node dissection for sentinel node-positive melanoma.
Hewitt DB; Merkow RP; DeLancey JO; Wayne JD; Hyngstrom JR; Russell MC; Gerami P; Balch CM; Bilimoria KY
J Surg Oncol; 2018 Sep; 118(3):493-500. PubMed ID: 30098302
[TBL] [Abstract][Full Text] [Related]
26. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer N; Berking C; Sunderkötter C; Kaatz M; Schulte KW; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Martus P; Garbe C;
Lancet Oncol; 2016 Jun; 17(6):757-767. PubMed ID: 27161539
[TBL] [Abstract][Full Text] [Related]
27. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
Eroglu Z; Broman KK; Thompson JF; Nijhuis A; Hieken TJ; Kottschade L; Farma JM; Hotz M; Deneve J; Fleming M; Bartlett EK; Sharma A; Dossett L; Hughes T; Gyorki DE; Downs J; Karakousis G; Song Y; Lee A; Berman RS; van Akkooi A; Stahlie E; Han D; Vetto J; Beasley G; Farrow NE; Hui JYC; Moncrieff M; Nobes J; Baecher K; Perez M; Lowe M; Ollila DW; Collichio FA; Bagge RO; Mattsson J; Kroon HM; Chai H; Teras J; Sun J; Carr MJ; Tandon A; Babacan NA; Kim Y; Naqvi M; Zager J; Khushalani NI
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002183
[TBL] [Abstract][Full Text] [Related]
28. In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?
Thompson JF
Ann Surg Oncol; 2021 Nov; 28(12):6915-6917. PubMed ID: 34365560
[No Abstract] [Full Text] [Related]
29. Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for Melanoma.
Sinnamon AJ; Song Y; Sharon CE; Yang YX; Elder DE; Zhang PJ; Xu X; Roses RE; Kelz RR; Fraker DL; Karakousis GC
Ann Surg Oncol; 2018 Nov; 25(12):3469-3475. PubMed ID: 30043316
[TBL] [Abstract][Full Text] [Related]
30. Time to reconsider the role of sentinel lymph node biopsy in melanoma.
Bigby M; Zagarella S; Sladden M; Popescu CM
J Am Acad Dermatol; 2019 Apr; 80(4):1168-1171. PubMed ID: 30471314
[TBL] [Abstract][Full Text] [Related]
31. Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival.
Woeste MR; McMasters KM; Egger ME
J Am Coll Surg; 2021 Apr; 232(4):517-524.e1. PubMed ID: 33316426
[TBL] [Abstract][Full Text] [Related]
32. The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086).
Tropea S; Del Fiore P; Maurichi A; Patuzzo R; Santinami M; Ribero S; Quaglino P; Caliendo V; Borgognoni L; Sestini S; Giudice G; Nacchiero E; Caracò C; Cordova A; Solari N; Piazzalunga D; Tauceri F; Carcoforo P; Lombardo M; Cavallari S; Mocellin S;
BMC Cancer; 2022 Jun; 22(1):610. PubMed ID: 35659273
[TBL] [Abstract][Full Text] [Related]
33. Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost.
Hu Y; Briggs A; Gennarelli RL; Bartlett EK; Ariyan CE; Coit DG; Brady MS
Ann Surg Oncol; 2020 Dec; 27(13):5248-5256. PubMed ID: 32514805
[TBL] [Abstract][Full Text] [Related]
34. Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?
Senders ZJ; Bartlett EK; Mouw TJ; McMasters KM; Egger ME
Ann Surg Oncol; 2023 Jun; 30(6):3648-3654. PubMed ID: 36934378
[TBL] [Abstract][Full Text] [Related]
35. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection.
Essner R; Scheri R; Kavanagh M; Torisu-Itakura H; Wanek LA; Morton DL
Arch Surg; 2006 Sep; 141(9):877-82; discussion 882-4. PubMed ID: 16983031
[TBL] [Abstract][Full Text] [Related]
36. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
37. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
Mozzillo N; Pasquali S; Santinami M; Testori A; Di Marzo M; Crispo A; Patuzzo R; Verrecchia F; Botti G; Montella M; Rossi CR; Caracò C
Eur J Surg Oncol; 2015 Jul; 41(7):823-9. PubMed ID: 25800935
[TBL] [Abstract][Full Text] [Related]
38. [Sentinel node biopsy and lymph node dissection in the era of new systemic therapies for malignant melanoma].
Ulmer A; Kofler L
Hautarzt; 2019 Nov; 70(11):864-869. PubMed ID: 31605168
[TBL] [Abstract][Full Text] [Related]
39. Does the time interval between sentinel lymph node biopsy and completion lymph node dissection affect outcome in malignant melanoma? A retrospective cohort study.
Richtig G; Richtig E; Neiss AN; Quehenberger F; Gmainer DG; Kamolz LP; Lumenta DB
Int J Surg; 2020 Mar; 75():160-164. PubMed ID: 32036082
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
